British National Formulary January 2024 Update

This update contains 6 significant changes, 1 dose change, 4 new monographs and 1 new preparation.

Significant Changes:

• Budesonide with formoterol (Symbicort 200/6 Turbohaler®): updated to include dosing as reliever therapy for mild asthma.
• Co-cyprindiol: update to contra-indications and cautions for use.
• Dexamethasone: clarification of how dosing is expressed for reduction of peri- and neonatal morbidity and mortality.
• Factor IX fraction, dried: name change to factor IX.
• Isotretinoin (Roaccutane®): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age [MHRA/CHM advice].
• Obesity: updated guidance for management.

Dose Changes:

• Duloxetine [update to dosing for major depressive disorder].

New Monographs:

• Aquipta® [atogepant].
• Elfabrio® [pegunigalsidase alfa].
• Spevigo® [spesolimab].
• Voraxaze® [glucarpidase].

New Preparations: Zeyzelf® [rivastigmine].